The Coronavirus disease 2019 (COVID-19) pandemic continues to have a huge impact on the health and socio-economic conditions worldwide. Empirical therapy that reduces morbidity and mortality has been recommended in COVID-19 patients. Favipiravir, an oral broad-spectrum anti-viral agent, has been approved for the treatment of mild to moderate COVID-19 infections, in many countries, including India.
It has demonstrated promising results in terms of quick symptom control, rapid viral clearance, and pulmonary radiographic improvement. 1 This infographic highlights the clinical effectiveness of favipiravir as a promising COVID-19 therapeutic agent.